Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS)

详细信息    查看全文

• 作者：Rebecca Davies ; MSc^a ; Roberto Carrasco ; MSc^a ; Helen E. Foster ; MD^b ; Eileen M. Baildam ; MBChB^c ; S.E. Alice Chieng ; MBChB^d ; Joyce E. Davidson ; MBChB^e ; Yiannis Ioannou ; PhD^f ; Lucy R. Wedderburn ; PhD^f ; ^g ; Wendy Thomson ; PhD¹ ; ^h ; ⁱ ; Kimme L. Hyrich ; PhD¹ ; ^a ; ⁱ ; ^{kimme.hyrich@manchester.ac.uk" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Juvenile idiopathic arthritis ; Biologic therapy ; DMARD therapy ; Treatment
• 刊名：Seminars in Arthritis and Rheumatism
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：46
• 期：2
• 页码：190-195
• 全文大小：345 K

文摘

Initial treatment of juvenile idiopathic arthritis (JIA) is largely based on the extent of joint involvement, disease severity and ILAR category. The licensing of biologic therapies for JIA has expanded treatment options.

The aims of the study are (1) to describe treatment prescribing patterns in JIA over the first 3 years following first presentation to paediatric rheumatology and (2) to determine whether patterns of treatment have changed as biologics have become more widely available.

Methods

Children with at least 3 years of follow-up within the Childhood Arthritis Prospective Study (CAPS) were included.

For analysis, children were placed into one of five groups according to their initial presentation to paediatric rheumatology: oligoarthritis (oJIA), polyarthritis (pJIA), systemic (sJIA), enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA). Treatment patterns over 3 years were described.

Results

Of 1051 children, 58% received synthetic disease-modifying anti-rheumatic drugs (sDMARD) and 20% received biologics over the 3 years. Use of sDMARDs and biologics was higher in more severe disease presentations (sJIA and pJIA); however, 35% and 10% who presented with oJIA were also treated with sDMARDs and biologics, respectively. The number of children receiving sDMARD after 2006 was higher (p = 0.02); however, there was no difference in biologic prescribing before and after 2006 (p = 0.4).

Conclusions

A high proportion of children presenting with JIA received sDMARDs plus/minus biologics during 3 years of follow-up. This was most common for patients with severe JIA but was also prescribed for patients with oligoarticular disease, despite the lack of evidence for effectiveness in this category.